ArticleFrontiers in immunology2026
FBXW7 suppresses gastric cancer development and progression via ubiquitination-mediated degradation of MMP2.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) remains a major cause of cancer-related mortality, highlighting the need to clarify the stromal and post-translational mechanisms underlying its progression. Methods: We integrated single-cell RNA sequencing, independent transcriptomic cohorts, clinical tissue analyses, functional assays, co-immunoprecipitation (Co-IP), multiple immunofluorescence labeling, and a xenograft model to investigate the cellular distribution, biological function, and mechanisms of regulation for matrix metalloproteinase 2 (MMP2) in GC. Results: Single-cell analysis of paired tumor and adjacent normal tissues suggested an increased relative abundance of fibroblast populations and higher extracellular matrix-associated activity in GC tissues. MMP2 was preferentially expressed in cancer-associated fibroblasts, particularly in transcriptionally defined universal fibroblast-like and myofibroblastic CAF states. Trajectory analysis further suggested that the MMP2-high universal fibroblast-like population occupies an early and potentially transitional position along the fibroblast-state continuum. These findings were supported by an independent single-cell dataset, TCGA-STAD analysis, and tissue staining. In CAF-gastric cancer cell co-culture assays, CAFs enhanced tumor-cell migration and invasion, while modulation of the FBXW7-MMP2 axis altered these phenotypes. MMP2 overexpression promoted GC cell proliferation, migration, and invasion, whereas MMP2 silencing had the opposite effects. Mechanistically, FBXW7 interacted with the intracellular pool of MMP2, enhanced its K48-linked polyubiquitination, and reduced MMP2 protein stability through a proteasome-dependent process. FBXW7 overexpression attenuated MMP2-associated malignant phenotypes Conclusion: Our findings identify MMP2-high fibroblast states as an important stromal feature of GC and reveal FBXW7-associated regulation of intracellular MMP2 stability as a potential therapeutic vulnerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.